<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309425</url>
  </required_header>
  <id_info>
    <org_study_id>CR017782</org_study_id>
    <secondary_id>R331333PAI1064</secondary_id>
    <nct_id>NCT01309425</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Four-Way Crossover Study to Assess the Dose-Proportionality of the Pharmacokinetics of Tapentadol, Given as Tamper-Resistant Tablets, in Healthy Japanese and Korean Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose-proportionality of the pharmacokinetics of
      tapentadol (CG5503) in healthy Japanese and Korean adult male participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-dose, open-label, single-center, randomized, four-way crossover study, ie,
      participants and investigator know the identity of the drug, which is assigned by chance,
      like flipping a coin, and participants may receive different interventions sequentially
      during the study. The study will consist of 4 treatment periods. A single dose of tapentadol
      (CG5503) will be administered orally with 240 mL of water under fasted conditions. All
      participants will receive 1 of the following 4 oral treatments in each period.

      Treatment A: One 25-mg tablet (25 mg) of tapentadol (CG5503) Treatment B: One 50-mg tablet
      (50 mg) of tapentadol (CG5503) Treatment C: One 100-mg tablet (100 mg) of tapentadol (CG5503)
      Treatment D: Two 100-mg tablets (200 mg) of tapentadol (CG5503) Each period will be separated
      by 7 - 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile, as measured by Cmax, AUC, tmax, kel, t1/2</measure>
    <time_frame>Two days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Time of screening to end of treatment (up to 9.5 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) ER two 100-mg TRF</intervention_name>
    <description>200mg TRF single oral dose</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) ER 50-mg TRF</intervention_name>
    <description>50mg TRF single oral dose</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) ER 25-mg TRF</intervention_name>
    <description>25mg TRF single oral dose</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) ER 100-mg TRF</intervention_name>
    <description>100mg TRF single oral dose</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese and Korean male volunteers, inclusive

          -  Body mass index (BMI) between 18.5 and 25 kg/mÂ², inclusive, and a body weight of not
             less than 50 kg

          -  Japanese volunteers must have resided outside of Japan for no more than 5 years, and
             their parents and maternal and paternal grandparents are Japanese.

          -  Korean volunteers must have resided outside of Korea for no more than 5 years and
             their parents and maternal and paternal grandparents are Korean.

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease

          -  History of hematologic disease, coagulation disorders (including any abnormal bleeding
             or blood dyscrasias), lipid abnormalities

          -  History of significant pulmonary disease, including bronchospastic respiratory disease

          -  History of diabetes mellitus, renal or hepatic insufficiency, thyroid disease,
             neurologic or psychiatric disease, infection, or any other illness that the
             investigator considers should exclude the participant or that could interfere with the
             interpretation of the study results

          -  Use of any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for paracetamol-acetaminophen, within 14 days before the first
             dose of the study drug is scheduled

          -  History of, or a reason to believe a participant has a history of drug or alcohol
             abuse within the past 5 years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tapentadol</keyword>
  <keyword>NUCYNTA</keyword>
  <keyword>CG5503</keyword>
  <keyword>R331333</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy volunteer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

